References
- HicklinDJEllisLMRole of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol20052351011102715585754
- KerbelRSTumor angiogenesisN Engl J Med2008358192039204918463380
- Limaverde-SousaGSternbergCFerreiraCGAntiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agentsCancer Treat Rev201440454855724360358
- SchneiderBPShenFMillerKDPharmacogenetic biomarkers for the prediction of response to antiangiogenic treatmentLancet Oncol20121310e427e43623026828
- LambrechtsDLenzHJde HaasSCarmelietPSchererSJMarkers of response for the antiangiogenic agent bevacizumabJ Clin Oncol20133191219123023401453
- TocchettiCGGallucciGCoppolaCThe emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitorsEur J Heart Fail201315548248923325019
- FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
- YoussoufianHHicklinDJRowinskyEKReview: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapyClin Cancer Res20071318 Pt 25544s5548s17875787
- AprileGBonottoMOngaroECritical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical useDrugs2013732003201524277700
- LuDJimenezXZhangHSelection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapyInt J Cancer200297339339911774295
- MiaoHQHuKJimenezXPotent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2Biochem Biophys Res Commun2006345143844516682007
- PooneRMVaidyaARamucirumab: first global approvalDrugs20147491047105824916147
- PrewettMHuberJLiYAntivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumorsCancer Res1999595209521810537299
- BrunsCJLiuWDavisDWVascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastasesCancer20008948849910931447
- ZhuZHattoriKZhangHInhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth facto receptor 2. Correlation between antibody affinity and biological activityLeukemia20031760461112646950
- ClarkeJMHurwitzHITargeted inhibition of VEGF receptor 2: an update on ramucirumabExpert Opin Biol Ther20131381187119623803182
- SpratlinJLCohenRBEadensMPhase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2J Clin Oncol20102878078720048182
- FuchsCSTomasekJYongCJRamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialLancet20143839911313924094768
- SafranHTomasekJYongCJREGARD: a phase 3, randomized, double-blind trial of ramucirumab and best supportive care versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy: age subgroup analysisASCO Annual Meeting2014
- WilkeHVan CutsemEOhSCRAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)Gastrointestinal Cancers Symposium2014
- WilkeHVan CutsemEOhSCRAINBOW: a global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum-and fluoropyrimidine-containing combination therapy: results of a multivariate Cox regression analysis adjusting for prognostic factorsASCO Annual Meeting2014 abstract 4076
- Van CutsemEClinganPAnandaSRAINBOW: a global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) + PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy: a subgroup analysis of Western populationASCO Annual Meeting2014
- Al-BatranSHVan CutsemEOhSCRAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma – quality-of-life (QoL) resultsASCO Annual Meeting2014 abstract 4058
- YoonHHBendellJCFadiSBRamucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial. Presented at ASCO 2014 Annual MeetingJ Clin Oncol2014325 abstract 4004
- Eli Lilly and CompanyA study of ramucirumab (IMC-1121B) drug product (DP) and best supportive care (BSC) versus placebo and BSC as 2nd-line treatment in patients with hepatocellular carcinoma after 1st-line therapy with sorafenib (REACH) http://www.clinicaltrials.gov/ct2/show/NCT01140347?term=NCT01140347&rank=1. NLM identifier: NCT01140347Accessed September 25, 2014
- Eli Lilly and CompanyA study in second line metastatic colorectal cancer http://www.clinicaltrials.gov/ct2/show/NCT01183780?term=NCT01183780&rank=1. NLM identifier: NCT01183780Accessed September 25, 2014
- GrotheyATaberneroJRougierPA randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780). 2014 ASCO Annual MeetingJ Clin Oncol201230Suppl abstract TPS3634
- ZhuAXChauIBlancJ-FA multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR). 2012 ASCO Annual MeetingJ Clin Oncol201230Suppl abstract TPS4146. NCT01140347
- CamidgeDRBallasMSDubeySA phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (Mab) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC)J Clin Oncol201028Suppl7588
- DoebeleRCSpigelDTehfeMA phase 2 randomized open-label study of ramucirumab (IMC 1121B; RAM) in combination with first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): final results from non-squamous (NSQ) ptsJ Thorac Oncol20138S290
- GaronEBCaoDAlexandrisEJohnWJYurasovSPerolMA randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study designClin Lung Cancer20121350550922853980
- GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomized phase 3 trialLancet2014384994466567324933332
- Eli Lilly and CompanyAn open-label, multicenter, randomized, phase 2 study of a recombinant human anti-VEGFR-2 monoclonal antibody, IMC-1121B in combination with platinum-based chemotherapy versus platinum-based chemotherapy alone as first-line treatment of patients with recurrent or advanced non-small cell lung cancer (NSCLC) Available from: http://clinicaltrials.gov/show/NCT01160744. NLM identifier: NCT01160744Accessed September 25, 2014
- Eli Lilly and CompanyA randomized, double-blind, phase 2 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy Available from: http://clinicaltrials.gov/show/NCT01703091. NLM identifier: NCT01703091Accessed September 25, 2014
- AesoyRSanchezBCNorumJHLewensohnRViktorssonKLinderholmBAn autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cellsMol Cancer Res200861630163818922978
- GhoshSSullivanCAZerkowskiMPHigh levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancerHum Pathol2008391835184318715621
- SkobeMRockwellPGoldsteinNVosselerSFusenigNEBlocking angiogenesis results in tumor cell invasion suppressionNat Med19973122212279359696
- KonecnyGEMengYGUntchMAssociation between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsClin Cancer Res2004101706171615014023
- PriceDJMiralemTJiangSSteinbergRAvrahamHRole of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cellsCell Growth Differ20011212913511306513
- O’Sullivan CoyneGBurotto PichunMClinical experience with ramucirumab: outcomes in breast cancerExp Opin Biol Ther201414913511360
- Eli Lilly and CompanyA study of ramucirumab (IMC-1121B) in participants with breast cancer Available from: http://clinicaltrials.gov/ct2/show/results/NCT01256567. NLM identifier: NCT01256567Accessed September 25, 2014
- HotchkissKAAshtonAWSparanoJInhibition of endothelial cell function by docetaxel (Taxotere)Proc Am Assoc Cancer Res200041647
- MilesDWChanADirixLYPhase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol2010283239324720498403
- YardleyDARichardsPDReevesJAFinal results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC)J Clin Oncol201432Suppl abstract 1035
- Eli Lilly and CompanyStudy of IMC-18F1 or ramucirumab DP in combination with capecitabine or capecitabine on previously treated breast cancer patients Available from: http://clinicaltrials.gov/show/NCT01234402. NLM identifier: NCT01234402Accessed September 25, 2014
- MackeyJRRamos-VazquezMLipatovOPrimary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer Available from: http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_238Accessed September 25, 2014
- MilesDWde HaasSLDirixLYBiomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancerBr J Cancer20131910851052106023422754
- EllisLMAmerican Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomesJ Clin Oncol201432121277128024638016
- ReckMKaiserMMellemgaardADocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol201415214315524411639